Liquid Chromatography – Mass Spectrometry Method for the Determination of Gliclazide in Human Plasma and Application to a Pharmacokinetic Study of Gliclazide Sustained Release Tablets

Abstract

A sensitive and selective liquid chromatographic – mass spectrometric (LC-MS) method for the determination of gliclazide (CAS 21187–98–4) in human pasma has been developed. Sample treatment was based on protein precipitation with acetonitrile. Analytical determination was carried out on a C₁₈ column interfaced with a triple quadrupole mass spectrometer. Positive electrospray ionization was employed as the ionization source. The mobile phase was acetonitrile-water containing 10 mmol/1 ammonium acetate, pH 3.5 adjusted with acetic acid (75:25) at the flow rate of 1.0 ml/min. Both the analyte and the internal standard glipizide (CAS 29094–61–9) were detected by use of selected ion monitoring mode. The method was linear in the concentration range of 0.025–2.5μ g/mL. The lower limit of quantification (LLOQ) was 0.025 μg/mL. The intra- and inter-day relative standard deviation across three validation runs over the entire concentration range was less than 9.8%. The accuracy determined at three concentrations (0.05, 0.2 and 1.5 μg/mL for gliclazide) was within ±10.11% in terms of relative error (RE). The method herein described was successfully applied for the evaluation of pharmacokinetic profiles of gliclazide sustained release tablets in 18 healthy volunteers. The results show that AUC, T_max, C_max and T_1/2 between the test formulation and reference formulation have no significant difference (P > 0.05). Relative bioavailability is 96.7.4 ± 12.9%

Key words

Antidiabetics - CAS 21187–98-4 - Gliclazide, human plasma, liquid chromatography–mass spectrometry, pharmacokinetics

• References

• 1 Satyanarayana S, Kilari EK. Influence of nicorandil on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits. Mol Cell Biochem. 2006; 291: 101-105
• 2 Schernthaner G. Gliclazide modified release: A critical review of pharmacodynamic, metabolic and vasoprotective effects. Metabolism. 2003; 52: 29-34
• 3 Song DK, Ashcroft FM. Glimepiride block of cloned β-cell, cardiac and smooth muscle K. ATP.channels. Br J Pharmacol. 2001; 133: 193-199
• 4 Jennings PE, Belch JJF. Free radical scavenging activity of sulphonylureas:a clinical assessment of the effectiveness of gliclazide. Ter Arkh. 2001; 73: 27-31
• 5 Brien RC, Luo M, Balazs N. Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications. 2000; 14: 201-206
• 6 Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. DrugSaf. 2000; 14: 313-320
• 7 Ziegler O, Drouin P. Hemobiological properties of gliclazide. J Diabetes Complications. 1994; 8: 235-239
• 8 Fava D, Cassone-Faldetta M, Laurenti O, De luca O, Ghiselli A, De Mattia G. Gliclazide improves antioxidant status and nitric oxide mediated vasodilation in type-2 diabetes. Diabet Med. 2002; 19: 752-757
• 9 Foroutan SM, Zarghi A, Shafaati A, Khoddam A. Application of monolithic column in quantification of gliclazide in human plasma by liquid chromatography. J Pharm Biomed Anal. 2006; 42: 513-516
• 10 Sweetman SC. The Complete Drug Reference. 34th ed. London: The Pharmaceutical Press; 2005. p. 332.
• 11 Najib N, Idkaidek N, Beshtawi M, Bader M, Admour I, Alam SM et al. Bioequivalence evaluation of two brands of gliclazide 80 mg tablets (Glyzide & Diamicron) in healthy human volunteers. Biopharm Drug Dispos. 2002; 23: 192-202
• 12 Kuo CY, Wu SM. High-performance liquid chromatography with electrochemical detection for analysis of gliclazide in plasma. J Chromatogr A. 2005; 1088: 131-135
• 13 Maurer HH, Kratzsch C, Kraemer T, Peters FT, Weber AA. Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry. J Chromatogr B. 2002; 773: 63-73